Searchable abstracts of presentations at key conferences in endocrinology

ea0020p179 | Endocrine tumours and neoplasia | ECE2009

AIP immunostaining is increased with lanreotide therapy in individuals with acromegaly and predicts changes in IGF-1 levels in female patients

Chahal Harvinder , Ansorge Olaf , Karavitaki Niki , Carlsen Eivind , Wass John , Grossman Ashley , Korbonits Marta

Background: Recently mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene have been found to occur in familial and sporadic somatotroph adenomas. These tumours tend to respond less well to somatostatin analogues, are diagnosed at an earlier age and behave more aggressively. AIP is expressed in sporadic somatotroph adenomas (Leontiou, JCEM, 2008).Aim: To evaluate the change in AIP immunostaining in sporadic acromegaly patients treated...

ea0015p169 | Endocrine tumours and neoplasia | SFEBES2008

Menin-mutation negative MEN1-syndrome patients have no germline p27 (cyclin-dependent kinase inhibitor 1B) or AIP (aryl hydrocarbon receptor-interacting protein) mutations

Igreja Susana , Chahal Harvinder , Akker Scott , Gueorguiev Maria , Popovic Vera , Wass John , Grossman Ashley , Korbonits Marta

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant negative disorder characterised by the occurrence of multiple adenomas including hyperplasia and/or neoplasm of the parathyroid glands, pancreatic islets and pituitary glands. Germline mutations in the menin gene predispose to the MEN1 syndrome; however, about 10–20% of patients with MEN1 do not have a detectable menin mutation. Recently, a mouse strain with a MEN1-like phenotype has been re...

ea0015p179 | Endocrine tumours and neoplasia | SFEBES2008

Somatostatin analogues stimulate AMPK (AMP-dependent protein kinase), a metabolic enzyme with anti-proliferative effects

Leontiou Chrysanthia A , Schmid Herbert , McSheehy Paul , Grossman Ashley B , Korbonits Marta

Background: AMPK is a metabolic enzyme regulating the energy supply of the cell but it has antiproliferative effects as well via the up-regulation of the p53-p21 axis and inhibition of the mTOR-pathway. Somatostatin (SST) analogues reduce hormone secretion from somatotroph adenomas and tumour growth inhibition can also be achieved. SST affect several signalling pathways including the mTOR-pathway. mTOR is a mediator of a pro-proliferative pathway that can be inhibited by activ...

ea0014p590 | (1) | ECE2007

Ghrelin, inhibits AMPK (AMP-dependent protein kinase), a regulator of cell proliferation and metabolism

Leontiou Chrysanthia , Kola Blerina , Dalino Paolo , Salahuddin Nabila , Franchi Giulia , Grossman Ashley , Korbonits Marta

Background Ghrelin stimulates cell proliferation in a number of tissues including pituitary. AMPK, a heterotrimer kinase enzyme, is an important sensor and regulator of cellular energy balance. We have shown that ghrelin can change AMPK activity in various tissues and this mechanism could play a role in its metabolic effects. AMPK has recently been established to strongly inhibit cell proliferation and tumorigenesis. We therefore hypothesised that ghrelin stimulates cell proli...

ea0013p204 | Endocrine tumours and neoplasia | SFEBES2007

Endogenous MC4R receptors couple to multiple MAPK pathways in hypothalamic cell lines

Patel Mayur , Symonds Dawn , Jonas Kim , Vaisse Christian , Korbonits Marta , Fowkes Rob

Hypothalamic MC4R receptors are Galphas-coupled GPCR’s that mediate the satiety response to αMSH. MC4R expression predominates in the PVN/VMH regions of the hypothalamus, regulating satiety gene expression (e.g. Bdnf). Human MC4R mutations often result in compromised Galphas-cAMP-PKA signalling and obesity onset. However, downstream signalling pathways have yet to be elucidated. We have investigated the potential for αMSH to stimulat...

ea0013p205 | AMEND Young Investigator's Award | SFEBES2007

Ghrelin, a proliferative agent in the pituitary, inhibits AMPK (AMP-dependent protein kinase), an emerging regulator of cell proliferation and metabolism

Leontiou Chrysanthia , Kola Blerina , Dalino Paolo , Salahuddin Nabila , Franchi Giulia , Grossman Ashley , Korbonits Marta

Background: Ghrelin stimulates cell proliferation in a number of tissues including pituitary. AMPK, a heterotrimer kinase enzyme, is an important sensor and regulator of cellular energy balance. We have shown that ghrelin can change AMPK activity in various tissues and this mechanism could play a role in its metabolic effects. AMPK has recently been established to strongly inhibit cell proliferation and tumorigenesis. We therefore hypothesised that ghrelin stimulates cell prol...

ea0013p291 | Steroids | SFEBES2007

The effects of glucocorticoids on the expression of gluconeogenic and lipogenic enzymes in a rodent model of Cushing’s Syndrome

Lolli Francesca , Christ-Crain Mirjam , Kola Blerina , Fekete Csaba , Wittman Gabor , Grossman Ashley B. , Korbonits Marta

Background: Cushing’s syndrome results from chronic exposure to excessive levels of glucocorticoids (GC). The clinical manifestations associated with hypercortisolaemia are variable and differ widely in severity, including hypertension, apparent obesity and metabolic aberrations such as diabetes, dyslipidaemia, ultimately leading to changes similar to the metabolic syndrome. We hypothesised that GC might influence the expression of the genes involved in lipogenesis and gl...

ea0093oc25 | Oral communication 4: Pituitary and Neuroendocrinology | EYES2023

The genetic background of acromegaly in a tertiary referral centre in Krakow, Poland

Bogusławska Anna , Godlewska Magdalena , Rzepka Ewelina , Korbonits Marta , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: Acromegaly is the most genetically determined pituitary disease.Objectives: We studied the prevalence of syndromic disease and germline mutations (AIP, MEN1, GNAS, PRKAR1A, CDKN1b) in a cohort of unselected, consecutive patients with acromegaly.Materials and methods: A total of 133 patients (79 females, 54 males, age range 16–75 years) with somatotroph pituitary neuroendocrine tumor who were studied at t...

ea0094p80 | Neuroendocrinology and Pituitary | SFEBES2023

Integrated multi-omics data reveals distinct regulatory signatures and signaling pathways of aryl hydrocarbon receptor interacting protein (AIP) knockout cells

Barry Sayka , Rai Ashutosh , Haworth Oliver , Rajeeve Vinothini , Cutillas Pedro , Korbonits Marta

Introduction: Aryl hydrocarbon receptor interacting protein (AIP) is a multifunctional co-chaperone protein with wide-ranging effects. It acts as a tumour suppressor in the pituitary, but may have other roles including oncogenic function in other tissues. To explore the molecular mechanisms, we have performed transcriptomic and phosphoproteomic analysis of Aip-knockout mouse embryonic fibroblasts (Aip-KO MEFs) cells and integrated these data sets.<p class=...

ea0094p91 | Neuroendocrinology and Pituitary | SFEBES2023

A novel AIP deletion emphasising the variable phenotype of AIP-related pituitary neuroendocrine tumours

Benjamin Loughrey Paul , J Morrison Patrick , K Ellis Peter , R Mullan Karen , Korbonits Marta

A 16-year-old female presented with secondary amenorrhoea. Menarche was age 14 years and periods were less frequent over the preceding 12 months. There was no galactorrhoea, headache or visual field disturbance and no known family history of pituitary disease, tall stature or infertility. There were no clinical signs of Cushing’s disease or acromegaly and visual fields were full to confrontation. Height was 160 cm. Investigations showed a prolactin of 2,452 mIU/l (RR 102-...